(BAX) Baxter International - Ratings and Ratios
IV Solutions, Infusion Devices, Generic Injectables, Surgical Sealants, Dialysis
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.79% |
| Yield on Cost 5y | 0.75% |
| Yield CAGR 5y | -16.89% |
| Payout Consistency | 39.6% |
| Payout Ratio | - |
| Risk via 5d forecast | |
|---|---|
| Volatility | 34.3% |
| Value at Risk 5%th | 46.1% |
| Relative Tail Risk | -18.17% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.06 |
| Alpha | -53.21 |
| CAGR/Max DD | -0.37 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.608 |
| Beta | 0.903 |
| Beta Downside | 1.079 |
| Drawdowns 3y | |
|---|---|
| Max DD | 62.44% |
| Mean DD | 27.87% |
| Median DD | 26.02% |
Description: BAX Baxter International January 03, 2026
Baxter International Inc. (NYSE:BAX) is a U.S.-based, diversified healthcare company that markets a broad range of products-including sterile IV solutions, infusion devices, parenteral nutrition, generic injectables, surgical hemostats, advanced operating-room equipment, smart-bed systems, patient-monitoring tools, and respiratory devices-across hospitals, dialysis centers, ambulatory surgery facilities, and home-care settings.
The firm operates through three segments: Medical Products and Therapies; Healthcare Systems and Technologies; and Pharmaceuticals. Its distribution model blends a direct sales force with independent distributors, drug wholesalers, and specialty pharmacies, and it maintains a global footprint spanning North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
Key recent metrics: FY 2023 revenue reached approximately $12.5 billion, with the Medical Products and Therapies segment contributing roughly 65% of sales; operating margin hovered near 12%, reflecting steady cost-control despite inflationary pressure on raw materials. The aging U.S. population and rising chronic-disease prevalence continue to drive demand for Baxter’s infusion and renal-care solutions, while reimbursement reforms in Europe pose a modest upside-risk to margins.
For a deeper quantitative view, you might explore ValueRay’s interactive dashboard on Baxter’s valuation metrics.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: -341.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -0.97 > 1.0 |
| NWC/Revenue: 28.65% < 20% (prev 22.64%; Δ 6.01% < -1%) |
| CFO/TA 0.04 > 3% & CFO 749.0m > Net Income -341.0m |
| Net Debt (7.99b) to EBITDA (1.03b): 7.78 < 3 |
| Current Ratio: 1.84 > 1.5 & < 3 |
| Outstanding Shares: last quarter (514.0m) vs 12m ago 0.39% < -2% |
| Gross Margin: 35.39% > 18% (prev 0.38%; Δ 3501 % > 0.5%) |
| Asset Turnover: 46.18% > 50% (prev 44.11%; Δ 2.06% > 0%) |
| Interest Coverage Ratio: 0.13 > 6 (EBITDA TTM 1.03b / Interest Expense TTM 311.0m) |
Altman Z'' 4.18
| A: 0.15 (Total Current Assets 6.93b - Total Current Liabilities 3.77b) / Total Assets 21.07b |
| B: 0.70 (Retained Earnings 14.84b / Total Assets 21.07b) |
| C: 0.00 (EBIT TTM 41.0m / Avg Total Assets 23.87b) |
| D: 0.85 (Book Value of Equity 11.79b / Total Liabilities 13.85b) |
| Altman-Z'' Score: 4.18 = AA |
Beneish M -3.00
| DSRI: 1.10 (Receivables 1.78b/1.73b, Revenue 11.02b/11.77b) |
| GMI: 1.08 (GM 35.39% / 38.21%) |
| AQI: 0.96 (AQ_t 0.52 / AQ_t-1 0.55) |
| SGI: 0.94 (Revenue 11.02b / 11.77b) |
| TATA: -0.05 (NI -341.0m - CFO 749.0m) / TA 21.07b) |
| Beneish M-Score: -3.00 (Cap -4..+1) = A |
ValueRay F-Score (Strict, 0-100) 36.57
| 1. Piotroski: 3.50pt |
| 2. FCF Yield: 1.26% |
| 3. FCF Margin: 2.09% |
| 4. Debt/Equity: 1.34 |
| 5. Debt/Ebitda: 7.78 |
| 6. ROIC - WACC: -4.78% |
| 7. RoE: -4.77% |
| 8. Revenue Trend: -72.98% |
| 9. EPS Trend: data missing |
What is the price of BAX shares?
Over the past week, the price has changed by +0.98%, over one month by +1.66%, over three months by -15.49% and over the past year by -40.45%.
Is BAX a buy, sell or hold?
- StrongBuy: 4
- Buy: 2
- Hold: 11
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the BAX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 23.1 | 18.2% |
| Analysts Target Price | 23.1 | 18.2% |
| ValueRay Target Price | 15.2 | -22.4% |
BAX Fundamental Data Overview January 27, 2026
P/S = 0.9252
P/B = 1.4085
P/EG = 36.7693
Revenue TTM = 11.02b USD
EBIT TTM = 41.0m USD
EBITDA TTM = 1.03b USD
Long Term Debt = 8.75b USD (from longTermDebt, last quarter)
Short Term Debt = 755.0m USD (from shortTermDebt, last quarter)
Debt = 9.71b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.99b USD (from netDebt column, last quarter)
Enterprise Value = 18.18b USD (10.20b + Debt 9.71b - CCE 1.73b)
Interest Coverage Ratio = 0.13 (Ebit TTM 41.0m / Interest Expense TTM 311.0m)
EV/FCF = 79.06x (Enterprise Value 18.18b / FCF TTM 230.0m)
FCF Yield = 1.26% (FCF TTM 230.0m / Enterprise Value 18.18b)
FCF Margin = 2.09% (FCF TTM 230.0m / Revenue TTM 11.02b)
Net Margin = -3.09% (Net Income TTM -341.0m / Revenue TTM 11.02b)
Gross Margin = 35.39% ((Revenue TTM 11.02b - Cost of Revenue TTM 7.12b) / Revenue TTM)
Gross Margin QoQ = 33.51% (prev 40.25%)
Tobins Q-Ratio = 0.86 (Enterprise Value 18.18b / Total Assets 21.07b)
Interest Expense / Debt = 0.60% (Interest Expense 58.0m / Debt 9.71b)
Taxrate = 21.0% (US default 21%)
NOPAT = 32.4m (EBIT 41.0m * (1 - 21.00%))
Current Ratio = 1.84 (Total Current Assets 6.93b / Total Current Liabilities 3.77b)
Debt / Equity = 1.34 (Debt 9.71b / totalStockholderEquity, last quarter 7.24b)
Debt / EBITDA = 7.78 (Net Debt 7.99b / EBITDA 1.03b)
Debt / FCF = 34.72 (Net Debt 7.99b / FCF TTM 230.0m)
Total Stockholder Equity = 7.15b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.43% (Net Income -341.0m / Total Assets 21.07b)
RoE = -4.77% (Net Income TTM -341.0m / Total Stockholder Equity 7.15b)
RoCE = 0.26% (EBIT 41.0m / Capital Employed (Equity 7.15b + L.T.Debt 8.75b))
RoIC = 0.18% (NOPAT 32.4m / Invested Capital 17.70b)
WACC = 4.96% (E(10.20b)/V(19.91b) * Re(9.24%) + D(9.71b)/V(19.91b) * Rd(0.60%) * (1-Tc(0.21)))
Discount Rate = 9.24% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 230.0m)
Revenue Correlation: -72.98 | Revenue CAGR: -5.56% | SUE: N/A | # QB: 0
Additional Sources for BAX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle